Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Wins InterMune, But For A Price

This article was originally published in The Pink Sheet Daily

Executive Summary

With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.

You may also be interested in...



Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs

Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.

Roche’s Pirfenidone Bet Validates China Venture

China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.

ASCEND Data Puts InterMune’s Pirfenidone On Top

Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS077595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel